Lumenis (LMNS) provides energy-based, minimally invasive clinical solutions primarily for the aging population.
One other company is scheduled for the week of
LMNS's manager and joint managers are
LMNS scheduled a
LMNS has established a strong brand across diverse end-markets, consisting of its surgical, ophthalmic and aesthetic segments.
Some income statement metrics include
· 2013 revenue was up 6.4% verus 2012 to
· Gross profit was 54% and increased 15.4% to
· Operating income increase 9.7% to
· After tax income increased $149% to
LMNS believes that its focus on product development has resulted in its strongest pipeline of new products and applications in over a decade.
LMNS is an Israeli-based global company sponsored by Goldman. Most Isaeli-based global companies have done well in the IPO market.
LMNS's P/E ratio is a reasonable 32, and the new product pipeline is the strongest in over a decade.
The IPO rating on LMNS is a buy.
LMNS is a leading global, highly diversified and growing provider of innovative energy-based, minimally invasive clinical solutions primarily for the aging population.
It has established a strong brand and leadership position across diverse end-markets, consisting of its surgical, ophthalmic and aesthetic segments, and its products are utilized for both medically necessary and elective procedures.
LMNS focused product offerings include solutions for a wide range of minimally invasive procedures across those segments.
LMNS' focus on product development has resulted in its strongest pipeline of new products and applications in over a decade.
Specifically, LMNS expects to launch one to two new product platforms in each of its three segments by the end of 2014.
The principal target markets for LMNS' products are hospitals, outpatient clinics, ambulatory surgery centers, physicians' offices, private clinics and aesthetic chains.
Sales & Marketing
LMNS markets, sells and services its products primarily through its direct sales and service organization, which provides it with a strong presence in its key markets, including
LMNS sells to the remainder of its geographies through an extensive global distributor network, consisting of over 170 independent distributors in over 70 countries worldwide.
LMNS' service organization of over 200 people supports the growth of its global customer base and provides it with an attractive recurring revenue stream.
LMNS believes it is well-positioned to capitalize on the large and growing emerging markets opportunity, specifically the APAC region, where
No dividends planned
LMNS holds more than 140 patents in
LMNS believes that its patent portfolio alone may not provide a significant advantage over our competitors and therefore, the competitive advantage depends on LMNS's ability to leverage its current brand strength and existing market position
Competition arises from laser and other light-based products, as well as from other treatment modalities and alternate technologies that are not based upon laser or light-based technologies.
LMNS also faces competition from companies selling accessories to, and offering services for, its products, as well as companies selling devices, particularly in the aesthetic market, for home use. Competitors range in size from small, single product companies to large, multinational corporations, which may have greater resources than LMNS.
LMNS' principal direct competitors consist of the following companies:
Aesthetic -- Alma Lasers;
XT Hi-Tech Investments (1992) Ltd. and affiliates 31.4%
Use of proceeds
LMNS expects to net
operations and for other general corporate purposes, including but not limited to working capital requirements, capital expenditures, investments, research and development, product development and sales and marketing expenditures.
LMNS may also use a portion of the net proceeds for the potential acquisition of, or investment in, technologies, products or companies that complement its business, although LMNS has no understandings, commitments or agreements to consummate any such acquisition or investment.